Atlas Trials

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Clinical trial NCT05996484 · UNKNOWN

Trial details

NCT number
NCT05996484
Sponsor
Nanfang Hospital, Southern Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal CarcinomaNeoadjuvant Therapy
Start date
2023-09-01
Primary completion
2024-11-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.